Osmond Resources Limited

OSM

Osmond Resources Ltd. is an early-stage mineral exploration and development company, which engages in the discoveries for gold, nickel, copper, and rare earth elements within the prospective Fowler Domain and Nuyts Domain, both within the Gawler Craton in South Australia as well as western Victoria. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-04-22. The firm's projects include Salt Wells Project, Iberian One Project, Yumbarra Project, Fowler Project, Coorabie Shear Zone Project, Tallacootra Project and Sandford Project. The Salt Wells Project is located in Churchill County, Nevada, United States. The Salt Wells Project consists of approximately 276 mineral claims, covering an area of 36 square kilometers (km2). The firm's Australian Projects (Yumbarra Project, Fowler Project, Coorabie Shear Zone Project, Tallacootra Project and Sandford Project) are focused on exploration for gold, nickel, copper and rare earth elements (REE) within the highly prospective Fowler Domain and Nuyts Domain, both within the Gawler Craton in South Australia and western Victoria. The Iberian One Project is located in Spain.

Osteopore Limited

OSX

Osteopore Ltd. develops and markets bioresorbable polymer implants for neurosurgical, orthopaedic and maxillofacial surgeries. The firm is engaged in commercializing a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. The Company’s patented technology fabricates specific micro-structured scaffolds for bone regeneration through three-dimensional (3D) printing and bioresorbable material. The Company’s Osteoplug in plug and strip configuration fills craniotomy gaps effortlessly. The company also promotes bone tissue integration, from the skull to the bone flap. Its craniofacial products include Osteomesh, Osteoplug, and Osteoplug-C. The company also offers craniotomy, orbital floor reconstruction, socket preservation, cranioplasty patient-specific implants (PSI), craniosynostosis, guided bone regeneration, minimally invasive skull base surgery, endoscopic transsphenoidal skull base surgery, burr hole restoration with the shunt drainage system, mandible PSI, immediate implant loading, and more.

Oncosil Medical Ltd

OSL

OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in Macquarie, New South Wales. The company went IPO on 2005-08-15. The firm is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The firm has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.